Augmentation of the immune response with granulocyte-macrophage colony- stimulating factor and other hematopoietic growth factors

Current Opinion in Hematology

Volumn 6, Issue 3, 1999, Pages 169-175

  Mellstedt, Håkan ^a   Fagerberg, Jan ^a   Frödin, Jan Erik ^a   Henriksson, Lotta ^a   Hjelm Skoog, Anna Lena ^a   Liljefors, Maria ^a   Ragnhammar, Peter ^a   Shetye, Jayant ^a   Österborg, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CELL KILLING; DRUG EFFECT; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PLEIOTROPY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; TUMOR IMMUNITY;

ANTIBODY FORMATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNE TOLERANCE;

EID: 0032859976     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199905000-00008     Document Type: Article

References (61)

1. 1 Masucci G, Wersäll P, Ragnhammar P, Mellstedt H: Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody dependent cellular cytotoxicity. Cancer Immunol Immunother 1989, 29:288-292.
2. 2 Ragnhammar P, Frödin J-E, Trotta PP, Mellstedt H: Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 1994, 39:254-262.
3. 3 Sallusto F, Lanazaveccia A: Efficient presentation of soluble antigen by cultured human Dcs is maintained by GM-CSF plus IL-4 and downregulated by TNF-α. J Exp Med 1994, 179:1109-1118.
4. 4 Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-α cooperate in the generation of Langerhans cells. Nature 1992, 360:258-261.
5. 5 Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al.: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF. J Exp Med 1992, 176:1693-1702.
6. 6 Marcowicz S, Engleman E: Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 1990, 85:955-961.
7. 7 McCarthy SA: GM-CSF augmentation of T cell receptor dependent and T cell receptor independent thymocyte proliferation. Blood 1994, 83:713-723.
8. 8 Santoli D, Clark SC, Kreider BL, Maslin PA, Rovera G: Amplification of IL-2 driven T cell proliferation by recombinant human IL-3 and GM-CSF. J Immunol 1988, 141:519-526.
9. 9 Nagata M, Sedgwick JB, Busse WW: Differential effects of granulocytemacrophage colony-stimulating factor on cosinophil and neutrophil superoxide anion generation. J Immunol 1995, 155:4948-4954.
10. 10 Koenderman L, Hermans SW, Capel PJ, van de Winkel JG: Granulocytemacrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. Blood 1993, 81:2413-2419.
11. 11 Fabian I, Kletter Y, Mor S, Geller-Gernstein C, Ben-Yaakow M, Volovitz B, Golde DW: Activation of human eosinophil and neutrophil functions by haematopoietic growth factors: comparisons of IL-1, IL-3, IL-5 and GM-CSF. Br J Haematol 1992, 80:137-143.
12. 12 Charak BS, Agah R, Mazumder A: GM-CSF induced ADCC in bone marrow macrophages: application in bone marrow transplantation. Blood 1993, 81:3474-3479.
13. 13 Ho AD, Haas R, Wulf G, Knauf W, Ehrhardt R, Heilig B, et al.: Activation of lymphocytes induced by rhGM-CSF in patients with malignant lymphoma. Blood 1990, 75:203-212.
14. 14 Bendall LJ, Kortlepel K, Gottlieb DJ: GM-CSF enhances IL-2-activated natural killer cell lysis of clonogenic AML cells by upregulating target cell expression of ICAM-1. Leukemia 1995, 9:677-684.
15. 15 Scott P, Trinchieri G: The role of natural killer cells in host-parasite interactions. Curr Opin Immunol 1995, 7:34-40.
16. 16 Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993, 90:3539-3543.
17. 17 Lee C-T, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, Gabrilovich D, Carbone D: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997, 8:187-193. This paper presents an effective and practical gene therapeutic strategy. GM-CSF-transduced tumor cells induced accumulation of dendritic cells at the inoculation site.
18. + T cells were necessary for the therapeutic effects. Interferon gamma and monocyte chemoattractant protein-1 transduction had no effect.
19. 19 McLaughlin JP, Abrams S, Kantor J, Dobrzanski M, Greenbaum J, Schlom J, Greiner JW: Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity. J Immunother 1997, 20:449-459. These authors further confirm the results repealed by Lee et al. (Hum Gene Ther 1997, 8:187-193) and by Nagai et al. (Cancer Immunol Immunother 1998, 47;72-80) and add that IL-2- and IL-12-transduced tumor cells were ineffective.
20. 20 Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JLM, Bierer BE, Croop JM: Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998, 91:222-230. GM-CSF tumor cells were capable of rejecting a large tumor burden as compared with tumor cells transduced with other genes. Interestingly, other cells in addition to T cells seemed to mediate the specific tumor-killing effect. This finding might have great implications for the future development of tumor vaccination strategies.
21. + T cells as well as nonspecific activation of eosinophils and macrophages.
22. 22 Simons J, Jaffee E, Weber C, Levitsky H, Nelson W, Carducci M, et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997, 57:1582-1546. This paper confirms the feasibility of transducing tumor cells for clinical use and the polycellular antitumor response.
23. + T cell responses in anti-tumor immunity. Curr Opin Immunol 1998, 10:588-594.
24. 24 Svanholm C, Löwenadler B, Wigzell H: Amplification of T-cell and antibody responses in DNA-based immunization with HIV-1 Nef by co-injection with a GM-CSF expression vector. Scand J Immunol 1997, 46:298-303. Administration of GM-CSF cDNA is an effective way of delivering GM-CSF. It must be present locally to augment the immune response, indicating the importance of activating dendritic cells at the vaccination site.
25. 25 Gerloni M, Lo D, Ballou WR, Zanetti M: Immunological memory after somatic transgene immunization is positively affected by priming with GM-CSF and does not require bone marrow-derived dendritic cells. Eur J Immunol 1998, 28:1832-1838.
26. 26 Geissler M, Schirmbeck R, Reimann J, Blum HE, Wands JR: Cytokine and hepatitis B virus DNA co-immunizations enhance cellular and humoral immune responses to the middle but not to the large hepatitis B virus surface antigen in mico. Hepatology 1998, 28:202-210.
27. 27 Sin J-I, Sung J-H, Suh Y-S, Lee A-H, Chung J-H, Sung Y-C: Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine 1997, 15:1827-1833.
28. 28 Turner J, Tan J, Crucian B, Sullivan D, Ballester O, Dalton W, et al.: Broadened clinical utility of gene gun-mediated, granulocyte-macrophage colony-stimulating factor cDNA-based tumor cell vaccines as demonstrated with a mouse myeloma model. Hum Gene Thor 1998, 9:1121-1130.
29. 29 Samanci A, Yi Q, Fagerberg J, Strigárd K, Smith G, Rudén U, et al.: Pharmacological administration of granulocyte-macrophage colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol Immunother 1998, 47:131-142. This is the first randomized clinical trial showing the importance of administration of soluble GM-CSF at the vaccination site. Moreover, the exogenous protein antigen vaccine also induced an MHC class I-restricted T-cell response, probably facilitated by the administration of GM-CSF.
30. 30 Loibner H, Janzek E, Mayor P, Liehl E: Vaccination of rhesus monkeys with an anti-idiotype antibody mimicking Lewis Y: enhancement of the anti-tumor immune response by repeated administrations of recombinant human GM-CSF [abstract]. Antibody Immunoconjugates Radiopharm 1995, 8:64.
31. 31 Kwak LW, Young HA, Pennington RW, Weeks SD: Vaccination with syngeneic lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A 1991, 93:10972-10977.
32. 32 Gotumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM: Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993, 53:5841-5844.
33. + T cells. The T-cell response was mapped to the complementarity-determining regions of the heavy chain of the idiotypic immunoglobulin.
34. 34 Bergenbrant S, Yi Q, Österborg A, Björkholm M, Ösby E, Mellstedt H, et al.: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996, 92:840-846.
35. 35 Ragnhammar P, Masucci G, Frödin J-E, Hjelm A-L, Mellstedt H: Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with MAb 17-1A and granulocyte/macrophage-colony-stimulating factor. Cancer Immunol Immunother 1992, 95:158-164.
36. 36 Ragnhammar P, Fagerberg J, Frödin J-E, Wersäll P, Hansson L-O, Mellstedt H: Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 1995, 40:367-375.
37. 37 Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Wigzell H, Mellstedt H: Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995, 55:1824-1827.
38. 38 Fagerberg J, Ragnhammar P, Liljefors M, Hjelm A-L, Mellstedt H, Frödin J-E: Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996, 42;81-87.
39. 39 Ragnhammar P, Frödin J-E, Trotta PP, Mellstedt H: Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophago-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies. Cancer Immunol Immunother 1994, 39:254-262.
40. 40 Shetye J, Ragnhammar P, Liljefors M, Christensson B, Frödin J-E, Biberfoldt P, Mellstedt H: Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1998, 4:1921-1929. Analyzing effector functions at the tumor site during immunotherapy should be one of the most appropriate approaches to the study of mechanisms of importance. This study shows that relevant effector cells containing cytotoxic granulae infiltrated the tumor. An antitumor T-cell response seemed to be initiated with the induction of cytotoxic CD8 and CD4 T cells, probably as a result of an idiotypic network response. CD8 and CD4 T cells showed a differential display in the tumor.
41. 41 Tsuboi K, Kimura T, Sugiura K, Hashimoto I, Nishikawa M, Uyama M, Fujisawa J-I: Granulocyte-macrophage colony-stimulating factor expressed in T cells mediates immunity against herpes simplex virus type 1 encephalitis. J Infect Dis 1998, 178:16-26.
42. 42 Bundschuh D, Barsig J, Hartung T, Randow F, Döcke W-D, Volk H-D, Wendel AA: Granulocyte-macrophage colony-stimulating factor and IFN-γ restore the systemic TNF-α response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol 1997, 158:2882-2871.
43. 43 Wiltschke C, Krainer M, Wagner A, Linkesch W, Zielinski CC: Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp Hematol 1998, 23:402-406.
44. 44 Burgess AW, Begley CG, Johnson GR, Lopez AF, Williamson DJ, Mermod JJ, et al.: Purification and properties of bacterially synthesized human GM-CSF. Blood 1987, 69:443-451.
45. 45 Ageitos AG, Ino K, Ozerel I, Tarantolo S, Heimann DG, Talmadge JE: Restoration of T and NK cell function in GM-CSF mobilized stem cell products from breast cancer patients by monocyte depletion. Bone Marrow Transplant 1997, 20:117-123. Monocytes have been shown in several systems to be able to secrete factors with immune-suppressive activities. In vivo primed GM-CSF cells clearly produced T- and NK cell-suppressive factors. This information is of great importance for the utilization of GM-CSF as an immune-augmenting CSF.
46. 46 Ragnhammar P, Friesen H-J, Frödin J-E, Lefvert A-K, Hassan M, Österborg A, Mellstedt H: Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994, 84:4078-4087.
47. 47 Wadhwa M, Bird C, Fagerberg J, Gaines-Des R, Ragnhammar P, Mellstedt H, Thorpe R: Production of neutralizing granulocyte-macrophage colony-stimulating (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol 1996, 104:351-358.
48. 48 Elsässer D, Valerius T, Repp R, Weiner J, Deo Y, Kalden JR, et al.: HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996, 87:3803-3819.
49. 49 Stockmeyer B, Valerius T, Repp R, Heijnen AFM, Bühring H-J, Deo YM, et al.: Preclinical studies with FxγR bispecific antibodies end granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997, 57:696-701.
50. 50 Michon J, Gey A, Moutel S, Tartour E, Meresse V, Fridman W, Teillaud J-L: In vivo induction of functional FcγRI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). Br J Haematol 1998, 100:550-556.
51. 51 Rutella S, Rumi C, Testa U, Sica S, Teofili L, Martucci R, et al.: Inhibition of lymphocyte blastogenic response in healthy donors treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF): possible role of lactoferrin in interleukin-1 receptor antagonist. Bone Marrow Transplant 1997, 20:355-364.
52. + cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 1997, 89:1629-1634.
53. 53 Tanaka J, Mielcarek M, Torok-Storb B: Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. Blood 1998, 91:347-352. Treatment with G-CSF-mobilized peripheral blood stem cells reduces the severity of graft-versus-host disease. This might be explained by hyporeactive T cells. A reversible defect in T-cell signaling by a secreted monocyte product might be responsible. This effect may add positively to the stem cell-mobilizing effect of G-CSF in allogenic stem cell transplantation.
54. + cells and IL-10 concentration. Anti-IL-10 antibodies inhibited the immune suppressive effect of activated monocytes.
55. 55 Miller J, Prosper F, McCullar V: Natural killer (NK) cells ere functionally abnormal and NK cell progenitors are diminshed in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections. Blood 1997, 90:3098-3105.
56. 56 Suzu S, Yokota H, Yamada M, Yanai N, Saito M, Kawashima T, et al.: Enhancing effect of human monocytic colony-stimulating factor on monocyte tumoricidal activity. Cancer Res 1989, 49:5913-5917.
57. 57 Suzu S, Yanai N, Saito M, Kawashima T, Kasahara T, Saito M, et al.: Enhancement of the antibody-dependent tumoricidal activity of human monocytes by human monocytic colony-stimulating factor. Jpn J Cancer Res 1990, 81:79-84.
58. 58 Lu L, Shen RN, Zhou SZ, Wu B, Kim YJ, Lin ZH, et al.: Efficacy of recombinant human macrophage colony-stimulating factor in combination with whole-body hyperthermia in the treatment of mice infected with the polycythemia-inducing strain of the Freund virus complex. Exp Hematol 1991, 19:804-809.
59. 59 Warren MK, Ralph P: Macrophage growth factor CSF-1 stimulates human monocyte production of interferon, tumor necrosis factor, and colony stimulating activity. J Immunol 1986, 137:2281-2285.
60. 60 Motoyoshi K, Yoshida K, Hatake K, Saito M, Miura Y, Yanai N, et al.: Recombinant and native human urinary colony-stimulating factor directly auguments granulocytic and granulocyte-macrophage colony-stimulating factor production of human peripheral blood monocytes. Exp Hematol 1989, 17:68-71.
61. 61 Sakurai T, Yamada M, Simamura S, Mytoyoshi K: Antimetastatic effect of recombinant human macrophage-colony-stimulating factor against lung and liver metastatic B16 melanoma. Cancer Immunol Immunother 1997, 44:48-54.